Zapping resistant spots: radiation may buy more time for lung cancer patients on targeted drugs
NCT ID NCT06813664
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and doctors will monitor how long the cancer stays controlled. The goal is to delay the need for switching to a new drug, potentially extending the benefit of the current treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug XTX501 takes aim at Hard-to-Treat cancers
- New drug cocktail targets Hard-to-Treat lung cancer
- Radiation zaps may buy time for melanoma patients
- New hope for Hard-to-Treat lung cancer: targeted drug combo shows promise
- Gentler chemo combo offers hope for elderly lung cancer patients
- Simple blood test may predict immunotherapy success in lung cancer